Figure 8.

TAT-CPE^452-466 treatment impairs hippocampus-dependent memory acquisition and consolidation but not retrieval. A, Schematic representation of the experimental schedules to investigate the effect of TAT-CPE^452-466 in the DH on NPR, CFC, AFC, OFT, and EPM behavioral performance. B, Representative image of the DH region 30 min after injection with TAT-CPE^452-466. Biotin-TAT-CPE^452-466 were stained with 488-Streptavidin and indicated in green representing the infected cells. Nuclei were stained by DAPI and indicated in blue. Scale bar, 20 μm. C, In the NPR tests, compared with TAT-Con-treated mice, TAT-CPE^452-466-treated mice show a poorer performance. Unpaired t test, t = 2.709 df = 11, *p = 0.0203; TAT-Con group, n = 7; TAT-CPE^452-466 group, n = 6. D, With the microinjection 30 min before FC training, TAT-CPE^452-466-treated mice showed lower freezing responses in CFC test but not in the AFC test. Unpaired t test, t = 5.73 df = 11, ***p = 0.0001; TAT-Con group, n = 7, TAT-CPE^452-466 group, n = 6. E, In the OFT tests, there is no significant difference between TAT-Con-treated mice and TAT-CPE^452-466-treated mice both in time spent in the center and the traveled distance. F, With the microinjection after FC training, TAT-CPE^452-466-treated mice showed reduced freezing responses in the CFC test but not in the AFC test. Unpaired t test, t = 4.337 df = 14, ***p = 0.0007; TAT-Con group, n = 8, TAT-CPE^452-466 group, n = 8. G, In the EPM tests, TAT-CPE^452-466-treated mice showed no significant difference in the time in open arms and entries into open arms. H, With the microinjection 30 min before the CFC test and AFC test, compared with TAT-Con-treated mice, TAT-CPE^452-466-treated mice showed similar freezing responses both in the CFC test and AFC test.